ArticleBlood advances2025
Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma.
Article in Blood advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Anti-CD3/CD20 bispecific antibodies as salvage therapy after CAR-T failure in relapsed/refractory large B-cell lymphoma: a systematic review and meta-analysis.Annals of hematology · 2026Pooled it
- Efficacy-safety trade-off and patient selection: a meta-analysis informing clinical choice between CAR-T and bispecific antibodies for R/R B-NHL.Frontiers in immunology · 2026Pooled it
- Outcomes of real-world complete responders after fixed duration glofitamab in relapsed/refractory large B-cell lymphoma.Haematologica · 2026Article
- Article
- Real-World Efficacy and Safety of Glofitamab-Based Salvage Therapy in Chinese Patients With Relapsed or Refractory Aggressive B-Cell Lymphomas.American journal of hematology · 2026Observational
- Prognostic role of FDG-PET in patients with relapsed/refractory large B-cell lymphoma treated with CD3-CD20 directed bispecific antibodies: a multicentric analysis.European journal of nuclear medicine and molecular imaging · 2026Article
- Advances in targeted and cellular therapies for relapsed/refractory mantle cell lymphoma: immunotherapeutic strategies and challenges.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Real-world outcomes of bispecific antibody therapy after chimeric antigen receptor T-cell therapy in follicular lymphoma.Blood cancer journal · 2026Article
- Pseudo-autologous Stem Cell Transplant for the Treatment of Secondary Central Nervous System Lymphoma.Cureus · 2026Article
- 2026 Update on the Management of Diffuse Large B-Cell Lymphoma.American journal of hematology · 2026Review
- Article
- 6-month Progression-Free Survival (PFS6) as a prognostic factor in large B-cell lymphoma patients undergoing chimeric antigen receptor T-cell therapy: A real-world multicenter study.Annals of hematology · 2026Article
- Prognostic value of inflammation-based scores in patients with R/R LBCL treated with CD3×CD20 bispecific T-cell engagers.Blood advances · 2026Article
- Multicenter real-life evaluation of the Post-CAR prognostic index for patients with large B-cell lymphoma after CAR-T failure.Journal of hematology & oncology · 2026Article
- Integrating new and "old" cellular therapies in the evolving landscape of relapsed or refractory large B-cell lymphoma.Frontiers in oncology · 2026Review
- CD19 CAR-T cell therapy in large B-cell lymphoma: clinical evidence, resistance, toxicity, and precision strategies.Frontiers in immunology · 2026Review
- Case Report: Compromised response of memory-formed bystander T cells after CD19 CAR-T cell therapy following CD20 bispecific antibody therapy.Frontiers in immunology · 2026Article
- Selecting the best treatment approach and optimizing sequencing strategies in large B-cell lymphoma.Hematology. American Society of Hematology. Education Program · 2025Article
- Outcomes and treatment patterns of patients with primary mediastinal B-cell lymphoma after CAR-T cell therapy failure: A DESCAR-T analysis.HemaSphere · 2025Article
- Beyond the CAR-T horizon in mantle cell lymphoma.Blood advances · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractPatients with large B-cell lymphoma (LBCL) who experience relapsed disease after CD19-directed chimeric antigen receptor (CAR) T-cell (CAR-T) therapy have a poor prognosis. Bispecific antibodies (BsAbs) induce complete remissions in ∼35% of these cases. Hypothesizing overlapping LBCL-intrinsic resistance mechanisms as well as common poor prognosis predictors to CAR-T and BsAb therapy, we conducted a multicenter retrospective analysis including 92 patients with relapsed/refractory (R/R) LBCL treated with BsAbs after CAR-T failure. Overall response rate (ORR) was 43%, with a progression-free survival (PFS) of 2.8 months. Patients receiving BsAbs during early relapse (≤3 months) achieved a significantly worse outcome (ORR, 29%; PFS, 2.2 months) compared with patients with an intermediate (4-6 months; ORR, 54%; PFS, 3.7 months) or a late relapse (>6 months; ORR, 60%; PFS, 10.5 months). The benefit of later relapse was particularly notable in patients receiving BsAbs as first salvage therapy compared with those receiving a BsAb in subsequent lines (PFS not reached vs 2.7 months; overall survival not reached vs 9.1 months, respectively). In addition to early R/R state before BsAbs, elevated lactate dehydrogenase and higher International Prognostic Index score were significant predictors of poor outcomes to BsAb in multivariate Cox regression analyses. The finding that patients with early relapse after CAR-T respond particularly poorly to BsAb highlights the necessity for alternative treatment options in this high-risk patient cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.